Hypoparathyroidism Market Outlook Size, Drugs, Epidemiology Trends And Forecast To 2035

(MENAFN- IMARC Group) According to the IMARC Group, the hypoparathyroidism market reached a value of USD 398.6 Million in 2024. Looking forward, the 7MM to reach USD 884.5 Million by 2035, exhibiting a growth rate (CAGR) of 7.5% during 2025-2035. This can be attributed to the growing acceptability of stem cell therapy, which helps to repair injured or absent parathyroid tissue that produces PTH and controls calcium levels in the body.

Key Stats for Hypoparathyroidism Market

• Hypoparathyroidism Market Value (2024): USD 398.6 Million
• Hypoparathyroidism Market Forecast Value (2035): USD 884.5 Million
• Hypoparathyroidism Market Forecast CAGR (2025-2035): 7.5%
• United States has the largest patient pool for hypoparathyroidism and also represents the largest market for its treatment.

Hypoparathyroidism is an uncommon endocrine disorder defined by insufficient production or secretion of parathyroid hormone (PTH) by the parathyroid glands situated in the neck. The hypoparathyroidism market is expanding rapidly owing to several interconnected factors. Primarily, the market is driven by the increased awareness of rare endocrine disorders and advancements in diagnostics, which allow for earlier and more precise diagnoses. In line with these factors, traditional treatments rely on calcium and active vitamin D supplements, yet they can lead to complications like hypercalciuria and kidney stones, prompting demand for highly effective options. This need has driven the development and approval of PTH replacement therapies, which provide a more physiological approach by directly addressing hormone deficiency, thereby offering improved calcium regulation and reducing kidney-related risks.

Additionally, regulatory incentives, including orphan drug designation, are encouraging investment by offering benefits like extended market exclusivity and tax credits, which further propel the growth of the hypoparathyroidism market. Moreover, rising investments in research and partnerships among pharmaceutical organizations and academic institutions are accelerating the development of next-generation therapies and expanding clinical trials. In addition to this, as healthcare shifts towards personalized medicine, treatments tailored to individual patient needs are enhancing efficacy and patient quality of life. These advancements, alongside supportive government policies and a strong R&D pipeline, are expected to drive significant growth in the hypoparathyroidism market in the coming years.

Key Highlights:

• Anterior neck surgery is the most frequent cause of acquired hypoparathyroidism and accounts for over 75% of cases.
• The prevalence of hypoparathyroidism in the United States is estimated to be around 37 per 100,000 person-years.
• The overall prevalence of hypoparathyroidism in the EU is estimated to be 3.2 per 10,000 people in 2020, with a growth rate of about 0.04 cases per year.
• The majority of people with hypoparathyroidism are 45 years or older.
• The women-to-men ratio is roughly 3:1.

This report also provides a detailed analysis of the current marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Get your Sample of Hypoparathyroidism Market Insights for Free https://www.imarcgroup.com/hypoparathyroidism-market/requestsample

Most influential companies in the Hypoparathyroidism Market:

The market has been studied in the report with the detailed profiles of the key players operating in the market.

Ascendis Pharma
MBX Biosciences

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

About Us:

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact US:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email:

Tel No:(D) +91 120 433 0800

United States: +1 201971-6302

MENAFN05082025004122016232ID1109886193